Onconetix Corporation (ONCO) - מקדם חוב לטווח ארוך להון

The current operational momentum of Onconetix, Inc. (ONCO) remains volatile due to modest scales of operation, although revenue from diagnostics and men's health provides a baseline income. Growth relies on the expansion of the drug Entadfi, new B2B agreements, and the development of onco-hematological systems. This chart of the asset's value on GURU.Markets captures the 0.00 metric, while pressure is exerted by minimally invasive treatments and competition with industry behemoths for the urology market.

Onconetix, Inc. (ONCO) invests in the development of high-precision diagnostic tests for urology, requiring stable funding. The long-term debt-to-equity ratio reflects the proportion of borrowed funds with a maturity exceeding one year. This metric measures financial leverage, determining the business development's dependence on external creditors. Analysis of this long-term debt load chart allows for an assessment of the balance between bankruptcy risks and expansion rates. Low values confirm the company's financial autonomy.